INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
487.95 EUR
-11.6 (-2.32%)
Overall IUI1 gets a fundamental rating of 6 out of 10. We evaluated IUI1 against 68 industry peers in the Health Care Equipment & Supplies industry. IUI1 gets an excellent profitability rating and is at the same time showing great financial health properties. IUI1 is valued quite expensive, but it does show an excellent growth. These ratings could make IUI1 a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year IUI1 was profitable.
IUI1 had a positive operating cash flow in the past year.
Each year in the past 5 years IUI1 has been profitable.
Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
IUI1's Return On Assets of 14.19% is amongst the best of the industry. IUI1 outperforms 92.65% of its industry peers.
With an excellent Return On Equity value of 16.12%, IUI1 belongs to the best of the industry, outperforming 83.82% of the companies in the same industry.
With an excellent Return On Invested Capital value of 11.69%, IUI1 belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for IUI1 is in line with the industry average of 9.73%.
The last Return On Invested Capital (11.69%) for IUI1 is above the 3 year average (9.53%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
With an excellent Profit Margin value of 28.58%, IUI1 belongs to the best of the industry, outperforming 97.06% of the companies in the same industry.
IUI1's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 29.44%, IUI1 belongs to the best of the industry, outperforming 98.53% of the companies in the same industry.
In the last couple of years the Operating Margin of IUI1 has declined.
The Gross Margin of IUI1 (66.38%) is better than 75.00% of its industry peers.
In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
Compared to 1 year ago, IUI1 has more shares outstanding
Compared to 5 years ago, IUI1 has more shares outstanding
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.18
WACC9.94%
2.3 Liquidity
IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IUI1 (4.97) is better than 95.59% of its industry peers.
A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.20, IUI1 belongs to the best of the industry, outperforming 95.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.12%, which is quite impressive.
Measured over the past years, IUI1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.48% on average per year.
IUI1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.18%.
IUI1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.27% yearly.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.67% on average per year.
Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 14.12% on average per year.
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 66.30, which means the current valuation is very expensive for IUI1.
60.29% of the companies in the same industry are cheaper than IUI1, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of IUI1 to the average of the S&P500 Index (27.25), we can say IUI1 is valued expensively.
Based on the Price/Forward Earnings ratio of 57.49, the valuation of IUI1 can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 72.06% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.98, IUI1 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.3 | ||
| Fwd PE | 57.49 |
4.2 Price Multiples
67.65% of the companies in the same industry are cheaper than IUI1, based on the Enterprise Value to EBITDA ratio.
IUI1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 89.04 | ||
| EV/EBITDA | 56.19 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IUI1's earnings are expected to grow with 15.90% in the coming years.
PEG (NY)3.29
PEG (5Y)5.77
EPS Next 2Y16.35%
EPS Next 3Y15.9%
5. Dividend
5.1 Amount
No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IUI1 (1/12/2026, 7:00:00 PM)
487.95
-11.6 (-2.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.29%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap172.98B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts77
Price Target523.6 (7.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)-0.15%
PT rev (3m)2.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.15%
EPS NY rev (1m)0%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.65%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)1.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.3 | ||
| Fwd PE | 57.49 | ||
| P/S | 21.04 | ||
| P/FCF | 89.04 | ||
| P/OCF | 68.31 | ||
| P/B | 11.87 | ||
| P/tB | 12.11 | ||
| EV/EBITDA | 56.19 |
EPS(TTM)7.36
EY1.51%
EPS(NY)8.49
Fwd EY1.74%
FCF(TTM)5.48
FCFY1.12%
OCF(TTM)7.14
OCFY1.46%
SpS23.19
BVpS41.12
TBVpS40.28
PEG (NY)3.29
PEG (5Y)5.77
Graham Number82.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC9.94%
ROIC/WACC1.18
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.67%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year45.96%
EBIT Next 3Y24.75%
EBIT Next 5Y20.85%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.